Glioblastomas (GBMs) are the most common malignant primary brain tumors. Despite
multimodality aggressive therapies (surgery followed by chemoradiotherapy based on TMZ and
adjuvant TMZ), median overall survival is only 12 to 15 months. This dramatic behavior is
mainly due to the high invasiveness and proliferation rate of GBM.
In addition, GBM exhibits a high resistance to standard chemotherapy and radiotherapy.
Current strategies for the treatment of GBM are only palliative, and include surgical
resection (which is frequently incomplete due to the proximity of the tumour to vital brain
structures) and focal radiotherapy. A large number of chemotherapeutic agents (e.g.
alkylating agents such as TMZ and nitrosoureas such as carmustine) have also been tested, but
they display limited efficacy.
The current gold standard first line treatment for glioma for patients less than 70 years old
includes radiation and concurrent TMZ followed by adjuvant TMZ (i.e., the "Stupp regimen").
However, results are disappointing and there is an unmet medical need of new drugs in this
Glasdegib (SHH pathway inhibitor) is a rational therapeutic agent for patients with newly
diagnosed Glioblastoma since inhibits SHH pathway interfering with cancer stem cells and
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.